Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bicycle Therapeutics Plc ADR (BCYC)

Bicycle Therapeutics Plc ADR (BCYC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 363,488
  • Shares Outstanding, K 69,368
  • Annual Sales, $ 35,280 K
  • Annual Income, $ -169,030 K
  • EBIT $ -290 M
  • EBITDA $ -283 M
  • 60-Month Beta 1.63
  • Price/Sales 12.77
  • Price/Cash Flow N/A
  • Price/Book 0.60

Options Overview Details

View History
  • Implied Volatility 469.54% (+64.37%)
  • Historical Volatility 55.62%
  • IV Percentile 78%
  • IV Rank 59.75%
  • IV High 742.02% on 01/21/26
  • IV Low 65.03% on 04/01/25
  • Expected Move (DTE 5) 0.31 (6.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 227
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 8,953
  • Open Int (30-Day) 8,609
  • Expected Range 4.93 to 5.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.00
  • Number of Estimates 5
  • High Estimate -0.90
  • Low Estimate -1.09
  • Prior Year -0.80
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.18 +1.16%
on 02/12/26
7.34 -28.61%
on 01/22/26
-1.25 (-19.26%)
since 01/13/26
3-Month
5.18 +1.16%
on 02/12/26
7.83 -33.08%
on 11/28/25
-1.36 (-20.61%)
since 11/13/25
52-Week
5.18 +1.16%
on 02/12/26
13.11 -60.03%
on 02/18/25
-7.25 (-58.05%)
since 02/13/25

Most Recent Stories

More News
Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline

Travis Thompson appointed chief financial officer; to succeed Alethia Young Michael Method, M.D., MPH, MBA promoted to chief medical officer; to succeed Eric Westin, M.D....

BCYC : 5.24 (-2.24%)
Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026

Dose selection from Phase 2/3 Duravelo-2 trial and update on potential approval pathway expected in 1Q 2026 as company seeks feedback from multiple regulatory agencies ...

BCYC : 5.24 (-2.24%)
Novel Modalities Drive $668B Precision Oncology Expansion

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The global oncology market is projected to reach US$668.26 billion by 2034[1], as investors increasingly...

ONCY : 1.0600 (+26.99%)
PSTV : 0.2752 (+7.08%)
IMNM : 22.16 (-1.25%)
BCYC : 5.24 (-2.24%)
CELC : 104.51 (-0.34%)
Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline

Execution of a 15-year contract including an option to renew with UK Nuclear Decommissioning Authority for access to up to 400 tonnes of reprocessed uranium (RepU), with the potential to deliver tens of...

BCYC : 5.24 (-2.24%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plc - BCYC

NEW YORK , Dec. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bicycle Therapeutics plc ("Bicycle" or the "Company") (NASDAQ: BCYC). Such investors are...

BCYC : 5.24 (-2.24%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plc - BCYC

NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Bicycle Therapeutics plc ("Bicycle" or the "Company") (NASDAQ: BCYC). Such investors are...

BCYC : 5.24 (-2.24%)
ATTENTION BCYC Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky

New York, New York--(Newsfile Corp. - November 18, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Bicycle Therapeutics plc ("Bicycle Therapeutics plc") (NASDAQ: BCYC)...

BCYC : 5.24 (-2.24%)
Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ® ) technology,...

BCYC : 5.24 (-2.24%)
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results

Dose selection from Phase 2/3 Duravelo-2 trial and update on potential approval pathway expected in 1Q 2026 as company seeks feedback from multiple regulatory agencies ...

BCYC : 5.24 (-2.24%)
3 Stocks to Buy Under $10 That Could Triple From Here

Not all great investment opportunities are expensive.

IOVA : 2.57 (+1.98%)
BCYC : 5.24 (-2.24%)
SANA : 3.85 (+1.58%)

Business Summary

Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company. It is focused on developing medicines, referred to as Bicycles(R) for diseases which are underserved by existing therapeutics. Bicycle Therapeutics plc is based in Cambridge, United Kingdom.

See More

Key Turning Points

3rd Resistance Point 5.78
2nd Resistance Point 5.66
1st Resistance Point 5.45
Last Price 5.24
1st Support Level 5.12
2nd Support Level 5.00
3rd Support Level 4.79

See More

52-Week High 13.11
Fibonacci 61.8% 10.08
Fibonacci 50% 9.14
Fibonacci 38.2% 8.21
Last Price 5.24
52-Week Low 5.18

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar